Stem cells for age-related macular degeneration

<p> <br> </p> <p> L.K.&nbsp;Moshetova<sup>1</sup>, O.I.&nbsp;Abramova<sup>1</sup>, I.N.&nbsp;Saburina<sup>2,3</sup>, K.I.&nbsp;Turkina<sup>2</sup> </p> <p> <sup>1</sup>Russian Medical...

Full description

Bibliographic Details
Main Authors: L.K. Moshetova, O.I. Abramova, I.N. Saburina, K.I. Turkina
Format: Article
Language:Russian
Published: Prime-Media 2019-09-01
Series:РМЖ "Клиническая офтальмология"
Online Access:http://clinopht.com/upload/iblock/91a/91af5994a581787389081f894a3551e8.pdf
id doaj-bff7e9872eac42fd9ada18de51e6b3e2
record_format Article
collection DOAJ
language Russian
format Article
sources DOAJ
author L.K. Moshetova
O.I. Abramova
I.N. Saburina
K.I. Turkina
spellingShingle L.K. Moshetova
O.I. Abramova
I.N. Saburina
K.I. Turkina
Stem cells for age-related macular degeneration
РМЖ "Клиническая офтальмология"
author_facet L.K. Moshetova
O.I. Abramova
I.N. Saburina
K.I. Turkina
author_sort L.K. Moshetova
title Stem cells for age-related macular degeneration
title_short Stem cells for age-related macular degeneration
title_full Stem cells for age-related macular degeneration
title_fullStr Stem cells for age-related macular degeneration
title_full_unstemmed Stem cells for age-related macular degeneration
title_sort stem cells for age-related macular degeneration
publisher Prime-Media
series РМЖ "Клиническая офтальмология"
issn 2311-7729
2619-1571
publishDate 2019-09-01
description <p> <br> </p> <p> L.K.&nbsp;Moshetova<sup>1</sup>, O.I.&nbsp;Abramova<sup>1</sup>, I.N.&nbsp;Saburina<sup>2,3</sup>, K.I.&nbsp;Turkina<sup>2</sup> </p> <p> <sup>1</sup>Russian Medical Academy of Continuous Professional Education, Moscow, Russian Federation </p> <p> <sup>2</sup>Institute for Molecular and Personalized Medicine, branch of Russian Medical Academy of Continuous Professional Education, Moscow, Russian Federation </p> <p> <sup>3</sup>Institute of General Pathology and Pathophysiology, Moscow, Russian Federation </p> <p> <i>Unique biological properties of stem cells offer infinite opportunities to use them for numerous degenerative disorders. Thus, in ophthalmology cell replacement therapy is a prospective approach to manage irreversible retinal cell death in age-related macular degeneration. Currently, this disorder is the leading cause of disability, blindness, and reduced quality of life in people aged over 50 in developed countries and is therefore important medical social issue. None of current treatment approaches can either turn back or prevent pre-existing retinal cell degeneration. Therefore, cell replacement therapy and regenerative medicine are promising modalities since they are characterized by much greater prospects than traditional treatment. This paper reviews recent advantages in the treatment for this incurable disorder using various types of stem cells (i.e., mesenchymal, embryonic, and induced pluripotent stem cells). This paper first gives a brief overview of age-related macu lar degeneration and then describes the methods of retinal cell generation.</i> </p> <p> <i><b>Keywords</b>: age-related macular degeneration, stem cells, eye tissue regeneration, pluripotent stem cells, clinical application of stem cells, regenerative medicine, cell therapy, tissue engineering.</i> </p> <p> <b>For citation:</b><i> Moshetova L.K., Abramova O.I., Saburina I.N., Turkina K.I. Stem cells for age-related macular degeneration. Russian Journal of Clinical Ophthalmology. 2019;19(3):143–148.</i> </p> <i> <p> <b>About the authors:</b> </p> <p> <i><sup>1</sup>Larisa&nbsp;K.&nbsp;Moshetova — MD, PhD, Academician of RAS, Head of the Department of Ophthalmology, ORCID iD: 0000-0002-5899-2714;</i> </p> <p> <i><sup>1</sup>Olga&nbsp;I.&nbsp;Abramova — MD, postgraduate student of the Department of Ophthalmology, ORCID iD 0000-0002-6156-6126;</i> </p> <p> <i><sup>2,3</sup>Irina&nbsp;N.&nbsp;Saburina — PhD, Professor, Principal Researcher, Head of Laboratory, ORCID iD 0000-0003-2014-2535;</i> </p> <p> <i><sup>1</sup>Kseniya&nbsp;I.&nbsp;Turkina — MD, PhD, associate professor of the Department of Ophthalmology, ORCID iD 0000-0002-4989-7467.</i> </p> <p> <i><sup>1</sup>Russian Medical Academy of Continuous Professional Education. 2/1, Barrikadnaya Str., Moscow, 125993, Russian Federation.</i> </p> <p> <i><sup>2</sup>Institute for Molecular and Personalized Medicine. 7, Build. 2, 2<sup>nd</sup>&nbsp;Botkinskiy Pass., Moscow, 125284, Russian Federation.</i> </p> <p> <i><sup>3</sup>Institute of General Pathology and Pathophysiology.&nbsp;<br> 8, Baltijskaya Str., Moscow, 125315, Russian Federation.</i> </p> <p> </p> <p> <i><b>Contact information:</b>&nbsp;Olga&nbsp;I.&nbsp;Abramova, e-mail:&nbsp;<a href="mailto:abramovao2019@mail.ru">abramovao2019@mail.ru</a>.&nbsp;<b>Financial Disclosure:</b>&nbsp;no author has a financial or property interest in any material or method mentioned. There is no&nbsp;<b>conflict of interests. Received</b>&nbsp;17.07.2019.</i> </p> </i><br>
url http://clinopht.com/upload/iblock/91a/91af5994a581787389081f894a3551e8.pdf
work_keys_str_mv AT lkmoshetova stemcellsforagerelatedmaculardegeneration
AT oiabramova stemcellsforagerelatedmaculardegeneration
AT insaburina stemcellsforagerelatedmaculardegeneration
AT kiturkina stemcellsforagerelatedmaculardegeneration
_version_ 1717378258982404096
spelling doaj-bff7e9872eac42fd9ada18de51e6b3e22021-09-16T13:40:15ZrusPrime-Media РМЖ "Клиническая офтальмология"2311-77292619-15712019-09-0119330694Stem cells for age-related macular degenerationL.K. Moshetova0O.I. Abramova1I.N. Saburina2K.I. Turkina3Russian Journal of Clinical Ophthalmology, Publisher of «Medicina-Inform» Address for correspondence: Russia, 105064, Moscow, P.O. Box 399Russian Journal of Clinical Ophthalmology, Publisher of «Medicina-Inform» Address for correspondence: Russia, 105064, Moscow, P.O. Box 399Russian Journal of Clinical Ophthalmology, Publisher of «Medicina-Inform» Address for correspondence: Russia, 105064, Moscow, P.O. Box 399Russian Journal of Clinical Ophthalmology, Publisher of «Medicina-Inform» Address for correspondence: Russia, 105064, Moscow, P.O. Box 399<p> <br> </p> <p> L.K.&nbsp;Moshetova<sup>1</sup>, O.I.&nbsp;Abramova<sup>1</sup>, I.N.&nbsp;Saburina<sup>2,3</sup>, K.I.&nbsp;Turkina<sup>2</sup> </p> <p> <sup>1</sup>Russian Medical Academy of Continuous Professional Education, Moscow, Russian Federation </p> <p> <sup>2</sup>Institute for Molecular and Personalized Medicine, branch of Russian Medical Academy of Continuous Professional Education, Moscow, Russian Federation </p> <p> <sup>3</sup>Institute of General Pathology and Pathophysiology, Moscow, Russian Federation </p> <p> <i>Unique biological properties of stem cells offer infinite opportunities to use them for numerous degenerative disorders. Thus, in ophthalmology cell replacement therapy is a prospective approach to manage irreversible retinal cell death in age-related macular degeneration. Currently, this disorder is the leading cause of disability, blindness, and reduced quality of life in people aged over 50 in developed countries and is therefore important medical social issue. None of current treatment approaches can either turn back or prevent pre-existing retinal cell degeneration. Therefore, cell replacement therapy and regenerative medicine are promising modalities since they are characterized by much greater prospects than traditional treatment. This paper reviews recent advantages in the treatment for this incurable disorder using various types of stem cells (i.e., mesenchymal, embryonic, and induced pluripotent stem cells). This paper first gives a brief overview of age-related macu lar degeneration and then describes the methods of retinal cell generation.</i> </p> <p> <i><b>Keywords</b>: age-related macular degeneration, stem cells, eye tissue regeneration, pluripotent stem cells, clinical application of stem cells, regenerative medicine, cell therapy, tissue engineering.</i> </p> <p> <b>For citation:</b><i> Moshetova L.K., Abramova O.I., Saburina I.N., Turkina K.I. Stem cells for age-related macular degeneration. Russian Journal of Clinical Ophthalmology. 2019;19(3):143–148.</i> </p> <i> <p> <b>About the authors:</b> </p> <p> <i><sup>1</sup>Larisa&nbsp;K.&nbsp;Moshetova — MD, PhD, Academician of RAS, Head of the Department of Ophthalmology, ORCID iD: 0000-0002-5899-2714;</i> </p> <p> <i><sup>1</sup>Olga&nbsp;I.&nbsp;Abramova — MD, postgraduate student of the Department of Ophthalmology, ORCID iD 0000-0002-6156-6126;</i> </p> <p> <i><sup>2,3</sup>Irina&nbsp;N.&nbsp;Saburina — PhD, Professor, Principal Researcher, Head of Laboratory, ORCID iD 0000-0003-2014-2535;</i> </p> <p> <i><sup>1</sup>Kseniya&nbsp;I.&nbsp;Turkina — MD, PhD, associate professor of the Department of Ophthalmology, ORCID iD 0000-0002-4989-7467.</i> </p> <p> <i><sup>1</sup>Russian Medical Academy of Continuous Professional Education. 2/1, Barrikadnaya Str., Moscow, 125993, Russian Federation.</i> </p> <p> <i><sup>2</sup>Institute for Molecular and Personalized Medicine. 7, Build. 2, 2<sup>nd</sup>&nbsp;Botkinskiy Pass., Moscow, 125284, Russian Federation.</i> </p> <p> <i><sup>3</sup>Institute of General Pathology and Pathophysiology.&nbsp;<br> 8, Baltijskaya Str., Moscow, 125315, Russian Federation.</i> </p> <p> </p> <p> <i><b>Contact information:</b>&nbsp;Olga&nbsp;I.&nbsp;Abramova, e-mail:&nbsp;<a href="mailto:abramovao2019@mail.ru">abramovao2019@mail.ru</a>.&nbsp;<b>Financial Disclosure:</b>&nbsp;no author has a financial or property interest in any material or method mentioned. There is no&nbsp;<b>conflict of interests. Received</b>&nbsp;17.07.2019.</i> </p> </i><br>http://clinopht.com/upload/iblock/91a/91af5994a581787389081f894a3551e8.pdf